Over his 25-year career, Peter Handrinos has advised many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.
Mr. Handrinos advises boards of directors, management teams, and entrepreneurs on corporate and securities law matters, with an emphasis on mergers and acquisitions and financing transactions for life sciences and technology companies.
The Legal 500 US describes Mr. Handrinos as “one of the best life sciences lawyers in Boston.” He has been consistently recognized as a leader in Life Sciences and ranked in Band 1 in Corporate/M&A: Capital Markets by Chambers USA, where he is described by clients as “extremely experienced” with “very valuable insights across critical financing and governance matters.” Mr. Handrinos is recognized as a Life Sciences Star in the 2018 through 2020 editions of the LMG Life Sciences Guide. He has also been listed in the 2012 through 2020 editions of Best Lawyers in America as a leader in mergers and acquisitions.
Mr. Handrinos has led more than 40 IPOs since January 1, 2013, for life sciences and technology companies. He also regularly advises companies on mergers and acquisitions transactions. In addition, he handles private and public financing transactions for his clients. He has represented all of the major US investment banks as underwriter’s counsel.